Overexpression of Annexin A1 Inhibits Pyroptosis and Improves Dry Eye Signs by Regulating the TRIM72/Nrf2/HO-1 Signaling Pathway
Authors:
Open Access
- 1 January 2025
- journal article
- Published by Walter de Gruyter GmbH in Archivum Immunologiae et Therapiae Experimentalis
- Vol. 73 (1)
Abstract
This study aimed to investigate the therapeutic potential of annexin A1 (ANXA1) overexpression in improving the signs of dry eye disease (DED) and to elucidate the underlying molecular mechanism. A murine model of DED was established by topical application of 0.2% benzalkonium chloride (BAC), and human corneal epithelial (HCE-T) cells were exposed to 0.0005% BAC for in vitro experiments. ANXA1 was overexpressed using adenoviral vectors, and the effects on tear production, pyroptosis, and activation of the tripartite motif-containing protein 72 (TRIM72)/nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) signaling pathway were evaluated using Western blotting, Schirmer test, Terminal deoxynucleotidyl Transferase dUTP Nick End Labeling (TUNEL) assays, and fluorescent probe analyses. To further examine the role of TRIM72, its expression was silenced with specific small interfering RNA (siRNA), and the consequent impact on ANXA1-mediated therapeutic effects was assessed. ANXA1 expression was significantly reduced in both in vivo and in vitro DED models. Restoration of ANXA1 through overexpression significantly improved tear secretion and suppressed pyroptosis in the murine model. Similarly, in HCE-T cells, ANXA1 overexpression not only enhanced cellular proliferation but also significantly inhibited pyroptosis. Mechanistic investigations demonstrated that ANXA1 overexpression activated the TRIM72/Nrf2/HO-1 signaling pathway by increasing TRIM72, Nrf2, and HO-1 expression. Notably, silencing TRIM72 abolished the therapeutic effects of ANXA1 overexpression, thereby confirming that activation of this pathway is essential for mediating the protective effects of ANXA1 against DED. Overexpression of ANXA1 inhibits pyroptosis and improves dry eye signs by regulating the TRIM72/Nrf2/HO-1 axis.Keywords
This publication has 21 references indexed in Scilit:
- M2 Macrophage‐Derived Extracellular Vesicles Reprogram Immature Neutrophils into Anxa1hi Neutrophils to Enhance Inflamed Bone RegenerationAdvanced Science, 2025
- Loss of Endothelial Annexin A1 Aggravates Inflammation‐Induched Vascular AgingAdvanced Science, 2024
- Dry eye disease in the young: A narrative reviewThe Ocular Surface, 2023
- Annexin A1 is a cell-intrinsic metalloregulator of zinc in human ILC2sCell Reports, 2023
- Effects of hyperosmolarity on annexin A1 on ocular surface epithelium in vitroExperimental Eye Research, 2022
- Salivary gland transplantation for dry eye disease: Indications, techniques, and outcomesThe Ocular Surface, 2022
- Anti‐Oxidative and Anti‐Inflammatory Micelles: Break the Dry Eye Vicious CycleAdvanced Science, 2022
- Dry eye disease and proteomicsThe Ocular Surface, 2022
- Dry Eye DiseaseJAMA, 2022
- NLRP12- and NLRC4-mediated corneal epithelial pyroptosis is driven by GSDMD cleavage accompanied by IL-33 processing in dry eyeThe Ocular Surface, 2020